Shares of Codexis Inc. (NASDAQ:CDXS) were up 2.5% during trading on Thursday . The company traded as high as $4.15 and last traded at $4.12, with a volume of 87,317 shares. The stock had previously closed at $4.02.

A number of analysts have commented on CDXS shares. HC Wainwright reissued a “buy” rating on shares of Codexis in a report on Tuesday, May 10th. Zacks Investment Research lowered Codexis from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th.

The firm’s market capitalization is $165.19 million. The stock’s 50-day moving average is $4.03 and its 200-day moving average is $3.78.

Codexis (NASDAQ:CDXS) last posted its earnings results on Monday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The business earned $8 million during the quarter, compared to the consensus estimate of $7.49 million. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.07) earnings per share. On average, equities research analysts anticipate that Codexis Inc. will post ($0.25) EPS for the current year.

An institutional investor recently raised its position in Codexis stock. EAM Investors LLC raised its stake in Codexis Inc. (NASDAQ:CDXS) by 0.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 407,255 shares of the company’s stock after buying an additional 1,604 shares during the period. EAM Investors LLC owned 1.01% of Codexis worth $1,723,000 at the end of the most recent reporting period.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.